PT  - JOURNAL ARTICLE
AU  - Otiende, M
AU  - Nyaguara, A
AU  - Bottomley, C
AU  - Walumbe, D
AU  - Mochamah, G
AU  - Amadi, D
AU  - Nyundo, C
AU  - Kagucia, EW
AU  - Etyang, AO
AU  - Adetifa, IMO
AU  - Maitha, E
AU  - Chondo, E
AU  - Nzomo, E
AU  - Aman, R
AU  - Mwangangi, M
AU  - Amoth, P
AU  - Kasera, K
AU  - Ng’ang’a, W
AU  - Barasa, E
AU  - Tsofa, B
AU  - Mwangangi, J
AU  - Bejon, P
AU  - Agweyu, A
AU  - Williams, TN
AU  - Scott, JAG
TI  - Impact of the COVID-19 epidemic on mortality in rural coastal Kenya
AID  - 10.1101/2022.04.06.22273516
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.06.22273516
4099  - http://medrxiv.org/content/early/2022/04/07/2022.04.06.22273516.short
4100  - http://medrxiv.org/content/early/2022/04/07/2022.04.06.22273516.full
AB  - Background The impact of COVID-19 on all-cause mortality in sub-Saharan Africa remains unknown.Methods We monitored mortality among 306,000 residents of Kilifi Health and Demographic Surveillance System, Kenya, through four COVID-19 waves from April 2020-September 2021. We calculated expected deaths using negative binomial regression fitted to baseline mortality data (2010-2019) and calculated excess mortality as observed-minus-expected deaths. We excluded deaths in infancy because of under-ascertainment of births during lockdown. In February 2021, after two waves of wild-type COVID-19, adult seroprevalence of anti-SARS-CoV-2 was 25.1%. We predicted COVID-19-attributable deaths as the product of age-specific seroprevalence, population size and global infection fatality ratios (IFR). We examined changes in cause of death by Verbal Autopsy (VA).Results Between April 2020 and February 2021, we observed 1,000 deaths against 1,012 expected deaths (excess mortality -1.2%, 95% PI -6.6%, 5.8%). Based on SARS-CoV-2 seroprevalence, we predicted 306 COVID-19-attributable deaths (a predicted excess mortality of 30.6%) within this period. Monthly mortality analyses showed a significant excess among adults aged ≥45 years in only two months, July-August 2021, coinciding with the fourth (Delta) wave of COVID-19. By September 2021, overall excess mortality was 3.2% (95% PI -0.6%, 8.1%) and cumulative excess mortality risk was 18.7/100,000. By VA, there was a transient reduction in deaths attributable to acute respiratory infections in 2020.Conclusions Normal mortality rates during extensive transmission of wild-type SARS-CoV-2 through February 2021 suggests that the IFR for this variant is lower in Kenya than elsewhere. We found excess mortality associated with the Delta variant but the cumulative excess mortality risk remains low in coastal Kenya compared to global estimates.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in whole by the Wellcome Trust [OXF-COR03-2430]. JAGS and TNW are supported by Wellcome Trust Research Fellowships (214320 and 202800)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the KEMRI (Kenya Medical Research Institute) Scientific and Ethics Review UnitI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUnderlying individual data include geo-located residence and individual hospital records and hence would be high risk for identifiability. Intermediary data will be published on the Havard dataverse server under a CCBY 4.0 license.